Gastroretentive drug delivery systems (GRDDS) have emerged as an advanced approach to overcome the limitations of conventional oral dosage forms by prolonging gastric residence time and improving drug bioavailability. The objective of these systems is to remain buoyant in gastric fluid for extended periods, allowing controlled release of drugs and enhanced absorption of medications with limited absorption windows. Floating tablets achieve buoyancy using low-density excipients, such as gas-generating substances like sodium bicarbonate, or swellable polymers like hydroxypropyl methylcellulose (HPMC). Formulation strategies generally employ polymeric matrices, effervescent components, or coating technologies to regulate release kinetics and enhance stability. Evaluation parameters, such as floating lag time, total floating duration, and in vitro and in vivo correlation, are essential for assessing system performance. GRDDS can improve the therapeutic efficacy of medicines used in gastrointestinal disorders and those requiring localized gastric delivery. Despite significant advancements, variability in gastric motility and physiological factors limit the reproducibility and scalability of formulations. This review consolidates current progress and identifies future directions for optimized gastroretentive floating tablet technology. Keywords: Gastroretentive drug delivery system, Floating tablet, Buoyancy, bioavailability, Polymer, Sustained release, gastric retention.